DePuy Synthes Awarded U.S. Department of Defense Contract for Orthopaedic Products

Posted On May 16, 2017 By OrthoSpineNews In Recon /

RAYNHAM, Mass., May 15, 2017 /PRNewswire/ — DePuy Synthes*, part of the Johnson & Johnson Medical Devices Companies**, today announced it has been awarded a national contract from the U.S. Department of Defense for its orthopaedic products. Under the contract, DePuy Synthes will supply up to $260 million worth of orthopaedic products to the Defense Logistics Agency’s electronic catalog (ECAT) of medical products, which offers U.S. military medical treatment facilities worldwide access to a full spectrum of medical products for active U.S. military personnel and veterans.

“Our commitment to U.S. military servicemen, women and their families has spanned more than a century, and we are excited to continue that commitment by bringing our innovative orthopaedic products to U.S. military medical treatment facilities worldwide through the ECAT system,” said Juan-José Gonzalez, President, DePuy Synthes, U.S. “ECAT not only creates a more efficient online purchasing system, but it also enables us to deliver on our promise to provide products and capabilities that help to improve overall care and increase patient satisfaction.”

For more information, visit https://www.defense.gov/News/Contracts/Contract-View/Article/1165420/.

About DePuy Synthes
DePuy Synthes Companies, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes Companies solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

*Contracted through Johnson & Johnson Health Care Systems Inc. for DePuy Synthes Sales, Inc. spine orthopaedic products.

**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson’s Medical Devices segment.

The third-party trademarks used herein are the trademarks of their respective owners.
©DePuy Synthes 2017. All rights reserved.

SOURCE DePuy Synthes

OrthAlign, Inc. Announces JMHLW Approval for use of Direct Anterior HipAlign®and UniAlign™ in Japan

Posted On May 16, 2017 By OrthoSpineNews In Recon /

ALISO VIEJO, CA (PRWEB) MAY 15, 2017

OrthAlign, Inc., a privately held U.S.-based medical device and technology company providing orthopedic surgeons with advanced precision technologies, announced today that the Japanese Ministry of Health, Labour, and Welfare (JMHLW) has approved Direct Anterior HipAlign® for use in supine position Total Hip Arthroplasty (THA) surgeries and UniAlign™ for use in Unicompartmental Knee Arthroplasty (UKA) surgeries in Japan.

“I am very excited that OrthAlign technology will be available for use in Japan for supine position THAs and UKAs,” said Yukihide Minoda, MD, PhD of Osaka City University in Osaka, Japan. “I already use KneeAlign® for my TKAs and have found it to be a very important part of my surgeries. Clinically, it has been very valuable for my patients in Japan and I am very happy with the excellent outcomes. I expect the same with these new technologies.”

Recent statistics have shown that the direct anterior (supine position) approach is growing in popularity amongst Japanese surgeons as it arguably leads to quicker recovery, less pain, more normal function for Japanese patients after a hip replacement, and is more minimally invasive. HipAlign provides accurate cup placement positioning and does not require any pre-operative imaging, intraoperative fluoroscopy, or additional personnel in the operating room to control components outside of the sterile field.

Based on FDA cleared bench test data, HipAlign technology provides cup placement accuracy of ±3°, with at least 97% confidence. The system accounts for pelvic tilt when measuring the abduction and anteversion angles of the acetabular cup.

UniAlign establishes the mechanical axis of the tibia, determining the varus/valgus angle and the posterior slope angle of the cutting block relative to the tibia, for the transverse resection. The system has been validated in simulated use testing to achieve resection accuracy of ±2.0° in the coronal plane, ±3.0° in the sagittal plane and ±2.0 mm in depth. This accuracy has been validated with at least 90% confidence.

Just as KneeAlign and Posterior Approach HipAlign have been distributed in Japan through OrthAlign’s partner ZimmerBiomet Japan, so too will Direct Anterior HipAlign and UniAlign.

“We are very pleased with the Japanese Ministry’s approval for use of Direct Anterior HipAlign and UniAlign in Japan,” said James Young Kim, OrthAlign’s Vice President and General Manager of International. “There were approximately 20,000 supine position THAs and 8,000 UKAs completed in Japan during 2016, and these are the fastest growing procedures in joint replacement in the country. Japan is extremely important for OrthAlign’s international growth strategy and we will continue providing new technologies that address the market’s needs, following the successes of KneeAlign and Posterior Approach HipAlign. We are thrilled to be expanding our partnership with ZimmerBiomet Japan and hope we can continue our contribution in raising the standard of care for Japanese joint replacement surgeries.”

About OrthAlign, Inc.

OrthAlign is a privately held medical device and technology company, developing advanced technologies that deliver healthier and more pain-free lifestyles to joint replacement patients, globally. We provide healthcare professionals with cutting edge, computer-assisted surgical tools that seamlessly and cost-effectively deliver vital data and clinical results to optimize outcomes for our patients. For more information regarding OrthAlign, please visit http://www.orthalign.com.

“ORTHALIGN®, ORTHALIGN PLUS®, KNEEALIGN®, KNEEALIGN® 2, HIPALIGN®, and UNIALIGN™ are registered trademarks of OrthAlign, Inc.”

CURASAN Bone Graft Foam Debuts In LA Knee Fusion

Posted On May 15, 2017 By OrthoSpineNews In Biologics, Recon /

By JSHAMP – 5-11-2017

A California surgeon has performed the first U.S. bone graft using a pliable foam produced by Research Triangle Park–based medical biomaterials company CURASAN Inc.

Divakar Krishnareddy, M.D., used CURASAN’s CERASORB Ortho Foam bone graft product in a knee fusion procedure, technically called knee arthrodesis, at Los Angeles Community Hospital.

It was the first surgery using CERASORB since the U.S. Food and Drug Administration approved it in December 2016.

“It’s exciting to see a product that has both excellent handling and strong clinical evidence become available in the U.S.A.,” said Krishnareddy. “CERASORB Ortho Foam’s handling is very easy to adapt to underlying anatomy, preventing large gaps while allowing graft placement where you need it.”

READ THE REST HERE

Shoulder Basic Science Reconfirms Benefits of Inlay Arthroplasty

Posted On May 11, 2017 By OrthoSpineNews In Recon /

FRANKLIN, Mass., May 10, 2017 /PRNewswire/ — Arthrosurface, Inc., the Global Leader in Inlay Arthroplasty announced new evidence showing dramatic differences between the company’s inlay glenoid technology and the standard of care in total shoulder replacement.

According to a comparative study in the Journal of Shoulder and Elbow Surgery, the inlay glenoid (socket) design was far superior to the onlay alternative with respect to the biomechanical stability. “Increased stress on the implant edge resulted in loosening of all onlays through a rocking horse phenomenon, whereas none of the inlays became loose during testing,” said the lead author Jeffrey Gagliano, MD from the Boulder Bone and Joint in Colorado. Richard Hawkins, MD, from the Steadman Hawkins Clinic of the Carolinas, Greenville, SC and senior author of the study concluded, “given the results of the study, future research and development should be directed toward inlay glenoid prosthetic design, matching native anatomy and size variation.”

The American Academy of Orthopaedic Surgeons estimates about 53,000 people in the United States have shoulder replacement surgery each year. The benefits of replacing both sides of the joint with a total shoulder arthroplasty have been well established, however, glenoid loosening remains the Achilles Heel of the procedure.

“According to the literature, 2-10% of patients treated with a standard total shoulder replacement will require a revision procedure within the first decade following surgery due to onlay glenoid component loosening. Inlay arthroplasty may provide a solution to lower the revision burden on patients and the healthcare system,” said Matthias Schurhoff, VP of Clinical Operations and Scientific Affairs at Arthrosurface.

The company’s OVO™ Primary Stemless Shoulder System with inlay glenoid replacement was launched in the US in 2009 and has experienced excellent surgeon adoption. The inherent advantages are particularly well suited for younger and active patients requiring shoulder joint replacement surgery.

About Arthrosurface

Arthrosurface, Inc. is a global orthopedic medical technology business providing a broad portfolio of essential products and instrumentation used to treat upper and lower extremity conditions caused by trauma, injury and arthritic disease. The product offerings include devices, instruments and orthobiologics designed to preserve and restore joints so patients can regain and maintain an active lifestyle. The Company offers a variety of unique systems that provide less invasive technologies for surgeons in the treatment of a wide variety of joint pathologies. Founded in 2002, Arthrosurface markets and distributes its products in the US and around the world and has succeeded in helping patients return to activity for over 13 years. For more information, please go to our website at www.arthrosurface.com

SOURCE Arthrosurface, Inc.

OrthAlign, Inc. Announces Appointment of Andy Turner as Country Director of Australia and New Zealand

Posted On May 10, 2017 By OrthoSpineNews In Recon, Top Stories /

ALISO VIEJO, CA (PRWEB) MAY 09, 2017

OrthAlign, Inc., a privately held U.S.-based medical device and technology company providing orthopedic surgeons with advanced precision technologies, announced today the appointment of Andy Turner as Country Director of Australia and New Zealand to support continued growth and investment of OrthAlign technologies in that region of the world. He will be based in Sydney.

Andy has over twenty years experience in the orthopaedic industry, in both the sales and marketing functions. His career began in Europe with DePuy, followed by a move to Biomet, where he was responsible for launching the Vanguard knee system across Europe. Andy moved to Australia in 2008 and has held senior management and executive positions for Smith & Nephew and ZimmerBiomet, where he was responsible for marketing, sales, and product management of the orthopedic portfolios. During his career, he has successfully managed some of the largest global orthopedic brands, namely, Legion, CPCS, Polar, NexGen, Oxford, and CPT, respectively. Andy’s strong commercial acumen and sales drive has resulted in meeting corporate objectives and financial targets at every stage of his career. He holds an Honors Degree in Management with a Major in Physiology from Hallam University, Sheffield, UK.

“The addition of Andy as a local leader for OrthAlign in Australia and New Zealand is just one of many major investments that we are making in those very important markets. KneeAlign® has already established itself as one of the leading orthopaedic technologies in ANZ, but OrthAlign technology is just scratching the surface,” said James Young Kim, OrthAlign’s Vice President and General Manager of International. “Andy’s local presence will greatly enhance our continued efforts in customer expansion, growth in our portfolio of products, and focus in providing world class customer service to our surgeons, hospitals, and surgery centers. With 65,000 knee and 45,000 hip arthroplasties completed in Australia and New Zealand in 2016, we are excited about the growth opportunities that are before us.”

About OrthAlign, Inc.

“ORTHALIGN®, ORTHALIGN PLUS®, KNEEALIGN®, KNEEALIGN® 2, HIPALIGN®, and UNIALIGN™ are registered trademarks of OrthAlign, Inc.”

xm_south-philly.jpg.pagespeed.ic_.CnFnPDdh9Q.jpg

Dr. Richard Rothman Recognized As 100 Great Health Care Leaders To Know In 2017

Posted On May 4, 2017 By OrthoSpineNews In Recon, Top Stories /

4 MAY 2017 BY MACIE J HEYMAN

Richard H. Rothman, MD, Ph.D, Founder, Rothman Institute and Professor of Orthopaedic Surgery at Sidney Kimmel Medical College at Thomas Jefferson University, was named one of the 100 Great Health Care Leaders to Know in 2017, by Becker’s Hospital Review. The list was comprised of, “100 exemplary leaders of health care providers, government agencies, insurers and companies with successful track records leading their organizations.” Other notable leaders appearing on the list include: President of the Joint Commission, Director of the National Institutes of Health, Director of the World Health Organization, and the Secretary of Health and Human Services.

“It is an honor to be recognized by such a well-known medical publication,” said Dr. Rothman. “This list includes some of the best and brightest minds in medicine today. To be included with such select company is truly humbling.”

“Dr. Rothman is not just a leader, but a visionary in the world of orthopaedic medicine,” said Alexander R. Vaccaro, MD, Ph.D, MBA, President, Rothman Institute, Richard H. Rothman Professor and Chairman, Department of Orthopaedic Surgery, at Sidney Kimmel Medical College at Thomas Jefferson University. “He is a master clinician, a passionate educator, a dedicated researcher and a selfless philanthropist. He embodies all of the qualities a medical leader needs in this day and age. On behalf of all Rothman Institute we congratulate him on a recognition well deserved.”

READ THE REST HERE

Global Knee Replacement Devices Market to Grow at a CAGR of 3.25% by 2021: Growing Demand for Cementless Knee Replacement – Research and Markets

Posted On May 3, 2017 By OrthoSpineNews In Recon, Top Stories /

DUBLIN, May. 03, 2017 /PRNewswire/ —

Research and Markets has announced the addition of the “Global Knee Replacement Devices Market 2017-2021” report to their offering.

The global Knee Replacement Devices market to grow at a CAGR of 3.25% during the period 2017-2021.

The report, Global Knee Replacement Devices Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is growing demand for cementless knee replacement. Globally, among all knee replacement procedures, the majority of surgeons use cemented knee replacements devices. However, these cemented knee replacement devices have many post-operative complications after they have been implanted in the body.

According to the report, one of the major drivers for this market is high prevalence of knee-related issues. Knee-related disorders are some of the major global health issues, which affect most people above 40 years and are more specific for people aged above 60 years. Arthritis, trauma, back pain, and osteoporosis are the most common joint problems globally. Limited physical activity and unhealthy eating habits can negatively influence the body’s homeostasis.

Key vendors

Zimmer Biomet
DePuy Synthes
Stryker
Smith & Nephew
Exactech
ConforMis

Other prominent vendors

Aesculap Implant Systems
Arthrex
Arthrosurface
Baumer
Corentec
Others

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Market segmentation by procedure type

PART 07: Market segmentation by end-user

PART 08: Geographical segmentation

PART 09: Decision framework

PART 10: Drivers and challenges

PART 11: Market trends

PART 12: Vendor landscape

PART 13: Key vendor analysis

PART 14: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/l9kldn/global_knee

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

OrthAlign, Inc. Announces New Leadership Appointments to Drive and Support Corporate Growth Initiatives

Posted On May 1, 2017 By OrthoSpineNews In Recon, Top Stories /

ALISO VIEJO, CA (PRWEB) MAY 01, 2017

OrthAlign, Inc., a privately held U.S.-based medical device and technology company providing orthopedic surgeons with advanced precision technologies, announced today the executive appointment of Mike Bushlack as Chief Financial Officer and the promotion of James Young Kim as Vice President and General Manager of International.

Mike Bushlack comes to OrthAlign with over 15 years of financial leadership experience in the medical device industry, working with early growth stage and large multi-national companies. Prior to joining OrthAlign, Mike was Chief Financial Officer of Blue Belt Technologies, Inc. and held executive financial leadership and business development roles at ev3 Inc., Covidien, and Medtronic, garnering a proven track record of partnering with business teams to develop and implement strategic plans and financial processes and focus investments to drive growth and enhance entity value. Mike began his career at KPMG LLP in Minneapolis, where he was a Senior Manager.

James Kim has over 12 years of strategic marketing and sales experience in the medical and healthcare industry, responsible for strategic planning, product and brand management, product development, and multiple launch and global commercialization assignments. Since October 2013, James served as OrthAlign’s Vice President of Sales and Marketing, helping lead the organization through an important growth period, including expansion of OrthAlign technology into key international markets. Prior to joining OrthAlign, James served in key marketing roles with Allergan, CareFusion, and Johnson & Johnson, successfully managing the Natrelle®, Pyxis®, and OneTouch® brands, respectively. James received an MBA from the University of Southern California’s Marshall School of Business.

“The executive appointments of Mike and James are key elements in our continued efforts to successfully expand our customer reach, portfolio of products, and focus in providing world class customer service to our surgeons, hospitals, and surgery centers across the globe,” said Eric B. Timko, OrthAlign’s Chief Executive Officer and Chairman. “We are energized and excited about the growth opportunities before us and are heavily focused on our strategic initiatives as one of the leading technology companies in orthopaedics.”

About OrthAlign, Inc.

“ORTHALIGN®, ORTHALIGN PLUS®, KNEEALIGN®, KNEEALIGN® 2, HIPALIGN®, and UNIALIGN™ are registered trademarks of OrthAlign, Inc.”

Ortho Sales Partners Announces the Addition of Amanda Tracy as Senior Vice President of Business Development

Posted On May 1, 2017 By OrthoSpineNews In Recon, Spine /

SCOTTSDALE, ARIZONA (PRWEB) MAY 01, 2017

Ortho Sales Partners, a global leader in orthopedic sales commercialization services, is pleased to announce the addition of Amanda Tracy as Senior Vice President of Business Development, further filling out its team of orthopedic and spine industry veterans. Ms. Tracy is a talented and well respected industry leader that has spent her career helping companies find solutions to complex problems.

Ms. Tracy is the third high-profile hire for Ortho Sales Partners in recent months and comes at an opportune time as the business continues to grow by assisting companies approach commercialization while mitigating the risks associated with such a big task. In recent years, there has been a huge shift in the market that reveals a reduction of surgeon influence with the adoption of new technologies. Ortho Sales Partners works with orthopedic and spinal device manufacturers to leverage their significant relationships with surgeons, distributors and national buying groups to help their clients realize faster growth while taking advantage of the economies of scale that have been implemented.

Ms. Tracy joins Ortho Sales Partners with 20 plus years of professional expertise. Notable is her most recent 10 years spent as the Vice President of Global Market Development for Musculoskeletal Clinical Regulatory Advisors, LLC ( MCRA). Ms. Tracy established the business development function after joining MCRA during its early growth stage. Over tenure, Ms. Tracy played an instrumental role in expanding the firm’s portfolio services beyond its initial regulatory affairs service offering. Prior to MCRA, Ms. Tracy held senior product roles that included work for : Cyberonics ( LivaNova), Janssen Pharmaceutica (Johnson and Johnson ) and Eli Lilly and Company.

“I am thrilled to be able to join Ortho Sales Partners executive team at a true industry inflection point, when we can actualize the potential of novel approaches to technology sales execution and commercialization support.” said Ms. Tracy. “As a team, we will work to disrupt a fast-growing industry by building and launching innovative service products that extend Ortho Sales Partners’ current platform and build efficiencies for the industry.”

Maintaining her current geographical location in Southern California, Ms. Tracy will focus on accelerating Ortho Sales Partners innovative line of service offerings to support manufacturers, surgeons, distributors and investors alike. Ms. Tracy will also be representing the brands The De Angelis Group, Surg.io, OrthoExpress and OrthoSpineDistributors.com.

“We are thrilled to bring someone aboard with the pedigree and expertise of Amanda Tracy. We have had the pleasure of knowing her for more than 10 years and have seen first-hand the incremental value she brings to her employers and clients” said Josh Sandberg President, Ortho Sales Partners. “This hire is another example of our commitment to offering our clients the best possible strategies and outcomes.”

HOSPITAL WITH LOWEST READMISSION RATE SHARES MORE DATA

Posted On April 25, 2017 By OrthoSpineNews In Recon, Top Stories /

Elizabeth Hofheinz, M.P.H., M.Ed. • Thu, April 20th, 2017

Orange County California’s Hoag Orthopedic Institute (HOI), just released its 2017 Outcomes Report. In it, readers can find information regarding HOI’s previous year’s surgical volumes, care quality metrics, infection and readmission rates, and patient satisfaction scores.

HOI has performed the most joint replacements in California for five consecutive years. It has also had the lowest readmission rate in the nation for hip and knee replacements from 2012 through 2015.

In addition to the data on infection rates and volume, the report also highlights quality improvement initiatives, distinctions and innovations, details on HOI’s education and research program, compelling patient testimonials, and much more.

“Our quest to provide greater value and optimize outcomes in musculoskeletal care unfolds in this issue of our annual outcomes report,” said Sopida Andronaco, R.N., director of Performance Improvement and Clinical Outcomes for HOI. “The entire HOI staff works tirelessly to continually reach this exemplary level of excellence and we are proud to showcase their dedication and commitment to delivering quality care to our patients.”

READ THE REST HERE

Recon

DePuy Synthes Awarded U.S. Department of Defense Contract for Orthopaedic Products

Related Links

OrthAlign, Inc. Announces JMHLW Approval for use of Direct Anterior HipAlign®and UniAlign™ in Japan

CURASAN Bone Graft Foam Debuts In LA Knee Fusion

Shoulder Basic Science Reconfirms Benefits of Inlay Arthroplasty

Related Links

OrthAlign, Inc. Announces Appointment of Andy Turner as Country Director of Australia and New Zealand

Dr. Richard Rothman Recognized As 100 Great Health Care Leaders To Know In 2017

Global Knee Replacement Devices Market to Grow at a CAGR of 3.25% by 2021: Growing Demand for Cementless Knee Replacement – Research and Markets

Related Links

OrthAlign, Inc. Announces New Leadership Appointments to Drive and Support Corporate Growth Initiatives

Ortho Sales Partners Announces the Addition of Amanda Tracy as Senior Vice President of Business Development

HOSPITAL WITH LOWEST READMISSION RATE SHARES MORE DATA

Elizabeth Hofheinz, M.P.H., M.Ed. • Thu, April 20th, 2017